Compare LINC & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LINC | PGEN |
|---|---|---|
| Founded | 1946 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.4B |
| IPO Year | 2005 | 2013 |
| Metric | LINC | PGEN |
|---|---|---|
| Price | $40.94 | $4.12 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 5 |
| Target Price | ★ $45.00 | $8.33 |
| AVG Volume (30 Days) | 310.3K | ★ 2.8M |
| Earning Date | 05-11-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 100.00 | N/A |
| EPS | ★ 0.64 | N/A |
| Revenue | ★ $261,853,000.00 | $230,981,000.00 |
| Revenue This Year | $15.16 | $1,115.92 |
| Revenue Next Year | $9.02 | $81.04 |
| P/E Ratio | $64.10 | ★ N/A |
| Revenue Growth | ★ 32.98 | N/A |
| 52 Week Low | $17.29 | $1.23 |
| 52 Week High | $42.85 | $5.47 |
| Indicator | LINC | PGEN |
|---|---|---|
| Relative Strength Index (RSI) | 56.03 | 54.94 |
| Support Level | $38.92 | $3.91 |
| Resistance Level | $42.69 | $4.31 |
| Average True Range (ATR) | 1.57 | 0.19 |
| MACD | -0.14 | 0.00 |
| Stochastic Oscillator | 53.81 | 64.01 |
Lincoln Educational Services Corp provides diversified career-oriented post-secondary education to high school graduates and working adults. The company offers programs in automotive technology, skilled trades, healthcare services, hospitality services, and business and information technology. Its reportable segments include: Campus Operations and Transitional. The majority of the revenue is generated from the Campus Operations segment, which includes all campuses that are continuing in operation and contribute to the company's core operations and performance.
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.